Emerging therapeutic agents for lung cancer

Area of Science:

• Oncology
• Pharmacology
• Clinical Trials

Background:

• Lung cancer remains a leading cause of cancer mortality globally.
• Recent breakthroughs in molecular diagnostics and immunotherapy are driving innovation in lung cancer treatment.
• The US Food and Drug Administration has approved a significant number of new lung cancer therapies in the past five years.

Purpose of the Study:

• To review recent advances in lung cancer therapeutics, focusing on early-phase clinical trials (Phase I/II).
• To highlight novel drugs with new mechanisms of action or improved alternatives to existing therapies.
• To provide an up-to-date overview of emerging therapeutic agents for both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).

Main Methods:

• Review of first-in-human and early-phase clinical trials for lung cancer therapeutics.
• Categorization of emerging drugs into targeted agents, immunotherapies, and antibody drug conjugates.
• Summary of ongoing clinical studies and agents on the horizon.

Main Results:

• A new era of lung cancer management with promising efficacy and safety profiles.
• Development of novel therapeutic agents offering better alternatives or entirely new mechanisms of action.
• Expansion of treatment opportunities for patients lacking conventional chemotherapy options.

Conclusions:

• Emerging therapies, including targeted agents, immunotherapies, and antibody drug conjugates, represent significant progress in lung cancer treatment.
• Early-phase clinical trials are crucial for identifying and validating these novel therapeutic agents.
• Continued research and clinical studies are essential to further improve outcomes for lung cancer patients.